Biocon Biologics’ retinal disorder medication Yesafili gets public funding in Canada

Yesafili, available in vial and prefilled syringe presentations (2 mg/0.05 mL), was the first biosimilar to Eylea approved by Health Canada

Biocon Biologics receives FDA approval for Bosaya and Aukelso biosimilars

Biocon Biologics appoints Deepali Naair as Global Head - Brand & Corporate Communications

She was Group Chief Marketing Officer at CKA Birla Group in her last role

Biocon Biologics expands diabetes portfolio with FDA approval of Kirsty

Biocon Biologics receives MHRA UK approval for Vevzuo and Evfraxy, Denosumab Biosimilars

Vevzuo is authorized for the prevention of skeletal related events in adults with advanced malignancies involving bone

Biocon Biologics receives Health Canada approval for Yesafili

The approval is based on a comprehensive package of analytical, nonclinical, and clinical data

Biocon Biologics receives MHRA, UK approval for biosimilar YESINTEK

YESINTEK is indicated for the treatment of adults and children from the age of 6 years and olde

Biocon gets six-month extension on insulin supply pact in Malaysia

The company was awarded the insulins supply contract for a three-year period in 2022 through April 2025

Biocon Biologics secures strong market coverage for Yesintek in US

Express Scripts has added YESINTEK to the National Preferred Formulary (NPF) effective March 21, 2025

Biocon Biologics receives positive CHMP opinions for biosimilar Denosumab in Europe

The positive opinions are based on applications submitted by Biosimilar Collaborations Ireland Limited